Moreover, low EZH2 expression was associated with a shorter PFS in patients with colorectal cancer, independent of gene mutations in the downstream part of the EGFR pathway and miR-31 expression, suggesting that EZH2 expression is a useful and additional prognostic biomarker for anti-EGFR therapy. Here, EGFR is linked to colorectal cancer.